Health Canada Drug Establishment Licence (DEL) Recognition
We are pleased to announce that our laboratory is listed under a Drug Establishment Licence (DEL) by Health Canada following a comprehensive regulatory assessment based on submitted evidence, quality documentation and compliance information.
The Drug Establishment Licence framework is a key regulatory mechanism administered by Health Canada to oversee activities associated with pharmaceutical products intended for the Canadian market. The assessment process involves the review of quality systems, operational controls, technical capabilities and compliance documentation to ensure adherence to applicable regulatory expectations.
This recognition reflects our commitment to maintaining robust quality management systems, technical competence, data integrity and regulatory compliance in support of pharmaceutical and healthcare industries.
Significance of DEL Recognition
- Demonstrates alignment with international regulatory expectations
- Supports confidence in laboratory quality and compliance systems
- Reinforces commitment to data reliability and technical excellence
- Enhances credibility for pharmaceutical and healthcare stakeholders
- Strengthens support for global market and regulatory requirements
Our Commitment
At Eureka Analytical Services, quality and compliance remain at the core of our operations. We continuously invest in technical expertise, validated methodologies and quality assurance practices to support clients with reliable analytical solutions that meet evolving global regulatory expectations.
The listing can be independently verified through the official Health Canada Drug and Health Product Inspections database.